Need advice in managing cancer immunotherapy cardiotoxicity?

Request Assistance

FDA Public Workshop: Assessment of Cardiovascular Toxicities in Immuno-oncology Trials
Posted by Moslehi on January 22, 2018

On Friday, December 1, 2017, the U.S. Food & Drug Administration (FDA) announced a public workshop entitled, “Assessment of Cardiovascular Toxicities in Immuno-oncology Trials”. This workshop provided a forum for discussion of cardiovascular toxicities in immuno-oncology clinical trials. The workshop focused on the identification...

Read More
Manuscripts published in Circulation raise awareness for immune checkpoint inhibitor associated myocarditis
Posted by Moslehi on January 22, 2018

Two manuscripts published on November 21, 2017 of the journal Circulation bring additional awareness for the syndrome of immune checkpoint-inhibitor (ICI)-associated myocarditis. Thuny and colleagues (Hospital Nord, Marseille, France) present a case series of 30 patients with ICI-induced cardiotoxicity. Cardiotoxicity was diagnosed at a...

Read More
Cardio-Oncology highlighted at American Heart Association Annual Meeting 2017
Posted by Moslehi on January 22, 2018

There were several cardio-oncology sessions at the American Heart Association (AHA) annual meeting which occurred in November 2017 in Anaheim, California. A session called “The Emerging Science of Cardio-Oncology” focused on the rapidly evolving area of clinical practice in cancer patients with heart failure or acute coronary...

Read More
View All
connect with us

Outstanding paper by my colleagues @StanfordDeptMed! Led by @HanZhuMD @SeanM_Wu! Looking forward to many Bay Area #CardioOnc meetings & collaborations in the coming year! Also A+ #CardioOnc compendium for @JMCCardiology @Rongtian2! Great to work w/ @AartiAsnaniMD on this!

Although the risk for myocarditis related to immune checkpoint inhibitors is an estimated 1%, findings from a recent study highlight the need for improved ways to screen and treat for this potential side effect. @CardioOncology

KLB is the main reason that I was given a position @BrighamWomens when I was completing my postdoc in @kaelin_lab & the chance to start the #CardioOnc program. He worked tirelessly behind the scenes & content to give credit to others. I miss him dearly. @rblument1 @NMHheartdoc

On Demand Session at #AHA21 "#Inflammation: Too Much, Too Little, or Just Too Long?" hear from @annetkiraboc1 @CardioOncology @KathrynMooreLab on this interesting topic! Logon anytime to enjoy. @AHAMeetings @AHAScience